184042-58-8

Basic information

• Product Name: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE
• Synonyms: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE;tert-Butyl 4-(2-fluoroethyl)piperazine-1-carboxylate;1-Piperazinecarboxylic acid,4-(2-fluoroethyl)-,1,1-dimethylethyl ester
• CAS NO: 184042-58-8
• Molecular Formula: C11H21FN2O2
• Molecular Weight: 232.297
• Mol File: 184042-58-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE(184042-58-8)
• EPA Substance Registry System: 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE(184042-58-8)

Safety Data

• Hazardous Substances Data: 184042-58-8(Hazardous Substances Data)

Usage

General Description

1-(2'-fluoro)ethyl-4-(tert-butyloxycarbonyl)piperazine is a chemical compound consisting of a piperazine ring with a 2'-fluoroethyl and tert-butyloxycarbonyl groups attached to it. It is commonly used as a building block in the synthesis of pharmaceutical compounds due to its potential pharmacological properties. 1-(2'-FLUORO)ETHYL-4-(TERT-BUTYLOXYCARBONYL)PIPERAZINE has a wide range of applications in the pharmaceutical industry, particularly in the development of drugs targeting central nervous system disorders, such as depression, anxiety, and schizophrenia. Additionally, it has been studied for its potential as a target for antipsychotic drugs due to its interaction with dopamine receptors and other neurotransmitter systems.

Upstream product

• 383-50-6 2-fluoroethyl tosylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 762-51-6 1-fluoro-2-iodoethane 
• 762-49-2 2-fluoroethyl bromide 

Downstream Products

• 541505-04-8 N-(2-fluoroethyl)-piperazine 

Relevant articles and documents

Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)

The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies including pulmonary arterial hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or prognostic targ

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

PURINE COMPOUNDS

A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.